### Accepted Manuscript

Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR)

Sreekanth A. Ramachandran, Pradeep S. Jadhavar, Manvendra P. Singh, Ankesh Sharma, Gaurav N. Bagle, Kevin P. Quinn, Po-yin Wong, Andrew A. Protter, Roopa Rai, Son M. Pham, Jeffrey N. Lindquist

PII:	S0960-894X(17)30058-6
DOI:	http://dx.doi.org/10.1016/j.bmcl.2017.01.045
Reference:	BMCL 24621
To appear in:	Bioorganic & Medicinal Chemistry Letters
Received Date:	20 December 2016
Accepted Date:	13 January 2017



Please cite this article as: Ramachandran, S.A., Jadhavar, P.S., Singh, M.P., Sharma, A., Bagle, G.N., Quinn, K.P., Wong, P-y., Protter, A.A., Rai, R., Pham, S.M., Lindquist, J.N., Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR), *Bioorganic & Medicinal Chemistry Letters* (2017), doi: http://dx.doi.org/10.1016/j.bmcl.2017.01.045

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com

# Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR)

Sreekanth A. Ramachandran<sup>a</sup>, Pradeep S. Jadhavar<sup>a</sup>, Manvendra P. Singh<sup>a</sup>, Ankesh Sharma<sup>a</sup>, Gaurav N. Bagle<sup>a</sup>, Kevin P. Quinn<sup>b</sup>, Po-yin Wong<sup>b</sup>, Andrew A. Protter<sup>c</sup>, Roopa Rai<sup>b</sup>, Son M. Pham<sup>b,\*</sup> and Jeffrey N. Lindquist<sup>b,\*</sup>

<sup>a</sup>Integral BioSciences, Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh, 201306, India <sup>b</sup>Medivation, now Pfizer Inc., 525 Market Street, 36th Floor, San Francisco, California 94105, United States <sup>c</sup>Current address: Palo Alto Pharmaceutical Consulting Service

### ARTICLE INFO

Article history:

Available online

Received Revised

Accepted

ABSTRACT

The ATR pathway is a critical mediator of the replication stress response in cells. In aberrantly proliferating cancer cells, this pathway can help maintain sufficient genomic integrity for cancer cell progression. Herein we describe the discovery of **19**, a pyrazolopyrimidine-containing inhibitor of ATR via a strategic repurposing of compounds targeting PI3K.

2016 Elsevier Ltd. All rights reserved.

Keywords: ATR pyrazolopyrimidine DNA damage PI3K HTS

Damage to cellular DNA, from intrinsic and extrinsic sources, are dealt with constantly in normal human cells. The DNA-Damage Response (DDR) is a complex process that has mechanisms specifically tailored for the type of DNA damage encountered.<sup>1,2</sup> These mechanisms may involve activation of checkpoint response, cell-cycle arrest, and DNA-repair or apoptosis in response to DNA-damage. In normal, healthy cells this response results in either a correction of the damage, or, if the damage is too extensive to repair, leads to cell death via apoptosis. In cells with oncogenic transformation, the DNA-damage response may be upregulated to enable rapid division and deal with the increased replicative stress of the enhanced rate of cell division.<sup>3-6</sup> The approval of olaparib (formerly AZD2281)<sup>7</sup> by the US FDA in 2014 for the treatment of certain forms of advanced ovarian cancer demonstrated the clinical benefit of inhibiting one component of the DDR pathway namely poly(ADP-ribose) polymerase (PARP).<sup>8-10</sup>

Another critical component of the replication stress response is the ataxia telangiectasia and rad-3 related protein (ATR), a member of the phosphatidylinositol 3-kinase-related protein kinase (PIKK) family.<sup>11-13</sup> This family also includes the DNA-damage response proteins, ataxia telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK).<sup>14</sup> Together all three proteins maintain genomic surveillance and stability in proliferating cells. ATR is the primary responder to replication stress in cells, including replication stress due to treatment with DNA-damaging agents like gemcitabine and hydroxyurea.<sup>15</sup> In this scenario, ATR activates checkpoint response and regulates the transition of S-phase to G2-phase to allow time for DNA repair and reducing efficacy of DNA-damaging agents. In addition, in cells lacking proper p53 activity, and thus a proper regulation of G1 to S-phase, are more dependent upon ATR pathway for survival and proliferation. This makes ATR an attractive target to increase tumor sensitivity to DNA-damaging agents,<sup>16,17</sup> combine with other agents targeting DNA-Damage-Repair, such as PARP inhibitors,<sup>18</sup> or as a monotherapy in certain indications/genotypes.<sup>19</sup>

Recent reports have described utilizing homology between ATR and phosphoinositide 3-kinase (PI3K) as a means for guiding ATR inhibitor design.<sup>20-23</sup> Our labs have recently reported the discovery of small-molecule Bruton's tyrosine kinase (BTK) and PI3K $\delta$  dual inhibitors and we sought to employ this collection to identify inhibitors of ATR.<sup>24</sup> Towards this end, we selected compounds from our library of BTK and PI3K $\delta$  dual inhibitors and screened them against ATR at 0.5 and 5  $\mu$ M (Eurofins Scientific, Dundee, Scotland). The results from this initial screen are graphically illustrated in Figure 1.





Among the 299 compounds tested, 11 compounds inhibited ATR activity to >50% at 5  $\mu$ M whereas at 0.5  $\mu$ M only 1 compound inhibited ATR activity to >50%. Surprisingly, an analysis of ATR and PI3K $\alpha/\gamma$  inhibition showed relatively poor correlation of inhibitory activity between these protein targets, Figure 2. These results suggested that using PI3K homology to guide optimizations would not be feasible with this chemical series. Therefore we would likely need to construct single-point changes in order to identify the key binding interactions on ATR as part of a larger effort to improve our hits.



Figure 2. A. ATR % inhibition vs PI3Ka IC<sub>50</sub>; B. ATR % inhibition vs PI3Ky IC<sub>50</sub>.

To confirm activity as well as benchmark our starting point, we performed dose-response tests on several of our best compounds which identified one sub-micromolar and three single-digit micromolar hits, Table 1. Compound 1 immediately stood out as a molecule of interest, not only as it was the most potent from our screening series, but it also lacked significant activity against BTK and PI3K $\delta$  ((±)-1, BTK inh = 24%, PI3K $\delta$  inh = 52% at 100 nM) compared to the other hits. Moreover, (±)-1 had the largest lipophilic efficiency (LipE = 3.2) among the best hits.

#### Table 1. Hits from ATR screen



Before embarking on an optimization campaign, we wished to identify the parts of the molecule which were contributing to the inhibitory activity against ATR. Using 1 as the starting point, we identified possible regions of interaction before setting out to prepare the various derivatives, Figure 3. As the 4-aminopyrazolopyrimidine scaffold was a ubiquitous motif in this series, we speculated that the highlighted region was critical for affinity, likely serving as the kinase hinge binder. However, we could not discount the importance of the azaindolyl group towards ATR affinity at this stage even though no other screening hit contained this substituent. As compounds 1-4 had different *N*-1 substituents, we envisioned that this region was more amenable to changes, but perhaps space-filling would be an important feature.



Figure 3. Possible areas of ATR interaction and molecular targets.

Compounds 5-8 were designed to examine the importance of the hydrogen-bond donor/acceptor motifs of the 4aminopyrazolopyrimidine scaffold (5 and 6) and of the azaindolyl substituent (7 and 8). Compounds 9 and 10 tested the significance of space-filling for groups connected to N-1 and C-3. The syntheses of compounds 5-10 were prepared from commercially available materials and described in the supplementary material. The ATR inhibition results summarized in Table 2 effectively show a

complete loss in ATR binding when either the 4-amino group (5) or the nitrogen at position-5 (6) are removed. These results demonstrated that this hydrogen-bond donor/acceptor component is in fact a critical element for ATR binding within this molecule class. Replacing the *C*-3 azaindolyl with an indolyl (7) resulted in a more modest 7.5-fold loss in ATR IC<sub>50</sub>. Substituting the same azaindolyl with a pyridyl (8) resulted in a complete loss of activity against ATR. Interestingly, aminopyridine-containing derivative (9) which maintains all the hydrogen-bonding elements of 1 also had diminished activity against ATR albeit with a measurable IC<sub>50</sub> up to 30  $\mu$ M. Together, the results for compounds 7-9 suggest that while the hydrogen-bonding elements of the *C*-3 substitutent may be beneficial, the space-filling features are critical for activity against ATR. Considering the observed potency of 2 and 3, it's likely that the *para*-bromo substituent occupies sufficient space to achieve low-micromolar activity against ATR and only a 6.7-fold loss in activity compared to (±)-1. This result supports our previous supposition that the *N*-1 position is more amendable to change than other parts of the molecule.

NSC

### Table 2. Results for 1, 5-10.

Compound	ATR IC <sub>50</sub> ( $\mu$ M)	$\mathbf{Fold}^{\mathrm{a}}$	
(±)- <b>1</b>	0.212	1.0	
(±) <b>-5</b>	>30	$ND^{b}$	
(±) <b>-6</b>	>30	$ND^b$	
(±)- <b>7</b>	1.59	7.5	
(±)- <b>8</b>	>30	$ND^{b}$	
(±)- <b>9</b>	19.3	91	
10	1.42	6.7	

<sup>a</sup>Fold = compound IC<sub>50</sub>/( $\pm$ )-1 IC<sub>50</sub>.

, CC

<sup>b</sup>ND, fold not determined.

Having identified key ATR affinity elements within our molecule, we then turned our attention to exploring the effects of different groups at C-3. Starting from 4-amino-3-iodopyrazolopyrimidine, **I**, the desired analogs were prepared by alkylating N-1 with tetraline-2-mesylate and then derivatizing with various boronic acids or boronate esters (Scheme 1) to afford compounds **11**-**15**, Figure 4.



Scheme 1. Reagents and conditions: (a) R-X, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70-130 °C, 4 h; (b) Ar-B(OR)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 M aqueous Na<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 16 h.



Figure 4. Compounds 11-19.

The methylated indole derivative **11** effectively maintained affinity towards ATR and had a slight loss in potency (fold = 2.7) compared to  $(\pm)$ -**1**, Table 3. This further supports our hypothesis that the hydrogen-bonding capacity of the *C*-3 substituent is not an important factor in ATR binding. Somewhat surprisingly, isomeric indole adduct **12** was attenuated by nearly 10-fold compared to **11** and 22-fold compared to  $(\pm)$ -**1** indicating that stereoelectronic effects contributes at least partially towards ATR affinity. Connecting the azaindolyl group through the five-membered ring at the 3'-position (**13**) resulted in a complete loss of ATR activity. It's likely that this new orientation exceeds the limits of the binding pocket, however unfavorable stereoelectronic features cannot be discounted at this time. A similar effect was observed with naphthyridin-2-one analogue **14** which was over 100-fold less potent against ATR compared to ( $\pm$ )-**1**. We also attempted to improve the ATR affinity of **9** by adding another ring to the 2-aminopyridyl group, however the resulting analogue (**15**) was equipotent to **9** and 90-fold less potent relative to ( $\pm$ )-**1**. Taken together, these results begin to describe the binding pocket off of the *C*-3 position of the pyrazolopyrimidine scaffold, but additional studies such as crystallography would be required to fully define the steric and stereoelectronic features of this region.

#### Table 3. Results for 11-15.

Compound	<b>ATR IC</b> <sub>50</sub> (μM)	$\mathbf{Fold}^{a}$
(±)- <b>11</b>	0.580	2.7
(±)- <b>12</b>	4.62	22
(±)- <b>13</b>	>30	$ND^{b}$
(±)- <b>14</b>	22.4	106
(±)- <b>15</b>	19.1	90

<sup>a</sup>Fold = compound IC<sub>50</sub>/( $\pm$ )-1 IC<sub>50</sub>.

<sup>c</sup>ND, fold not determined.

Given that our C-3 modifications did not improve affinity towards ATR, we chose to maintain the azaindolyl group of **1** when investigating changes at pyrazolopyrimidine N-1. Following Scheme 1, we alkylated iodide **I** with a variety of electrophiles and then cross coupled with 7-azaindole-5-boronic acid pinacol ester to provide N-1 analogues **16-19**.

Among our first tasks was the resynthesis of  $(\pm)$ -1 and subsequent resolution of its enantiomers (1 and 1'). Although there appears to be a distinction between the two enantiomers of  $(\pm)$ -1 with respect to ATR affinity, the overall difference is not more than 2-fold (1 IC<sub>50</sub> = 0.304 µM vs. 1' IC<sub>50</sub> = 0.158 µM), Table 4. Indane-containing analogue 16 eliminates the stereogenic center and slightly alters the trajectory of the *N*-1 substituent. However, this modification does not improve but rather attenuates potency

against ATR by approximately 3-fold compared to ( $\pm$ )-1. We also employed the *N*-1 group present in 4. While 17 and 17' were an improvement relative to 4, they were essentially equipotent with respect to ( $\pm$ )-1 (17 fold = 1.3, 17' fold = 2.6). Analogue 18 utilizes a sulfonamide moiety illustrated in a series of ATR inhibitors recently reported by Barsanti *et al.*<sup>22</sup> However, this analogue performed no better than our initial hits providing low-micromolar potency against ATR, (18, IC<sub>50</sub> = 1.32  $\mu$ M). We also took inspiration from Vertex and employed a phenylsulfonyl group similar to VX970.<sup>25,26</sup> Satisfyingly, 19 was our best ATR inhibitor to date with an IC<sub>50</sub> = 0.066  $\mu$ M which represented a 3-fold improvement over screening hit ( $\pm$ )-1.

SCRÌ

Table 4. Results for 1, 17-20

Compound	ATR IC <sub>50</sub> ( $\mu$ M)	Fold <sup>a</sup>
1	0.304	1.4
1′	0.158	0.75
16	0.654	3.1
17	0.269	1.3
17´	0.547	2.6
18	1.32	6.2
19	0.066	0.31

 $^{a}$ Fold = compound IC<sub>50</sub>/(±)-1 IC<sub>50</sub>.

With a double-digit nanomolar ATR inhibitor in hand, we now had a practical analogue with which to obtain a PK-ADME and selectivity profile. To benchmark our development progress, we included clinical candidates VX970 and AZD6738<sup>27</sup> in our ATR and *in vitro* ADME studies alongside **19**. In our hands, VX970 had an  $IC_{50} = 0.015 \mu$ M against ATR and AZD6738 had an  $IC_{50} = 0.086 \mu$ M, Table 5. It's worth noting that reported results for both agents were considerably lower (VX970, lit.  $K_i < 0.2 n$ M; AZD6738, lit.  $IC_{50} = 1 n$ M) compared to our tests which is likely a result of differences in assay methodologies. Nonetheless, **19** appears to be comparable to both clinical candidates from a biochemical potency standpoint. Moreover, the lipophilic efficiency of **19** was calculated to be 5.8 which is comparable if not an improvement to VX970 and AZD9738. The *in vitro* metabolism assays were performed with either human, mouse or rat liver microsomes, which were supplemented with NADPH to assess oxidative stability (hLM, mLM or rLM). The results for all three compounds demonstrate reasonable oxidative stability across the species tested.

### Table 5. ATR IC<sub>50</sub>'s (µM) and *in vitro* ADME for 19, VX970 and AZD6738.

		ĺ	Ŝ	NH <sub>2</sub> O-N N O=S O CH <sub>3</sub>	- NH	CH3 N N N N N N N CH3 O NH
			,	N	/X970	AZD6738
Cmpd	<b>ATR IC<sub>50</sub></b> (μM)	LipE	<b>hLM</b> <sup>a</sup>	<b>mLM</b> <sup>a</sup>	rLM <sup>a</sup>	
19	0.066	5.8	83	79	63	
VX970	0.015	4.7	71	77	80	
AZD6738	0.086	5.2	84	68	93	

<sup>a</sup>Percent parent remaining (%R) after 30 min.

Compound **19** was tested for off-target activity in a panel of 394 kinases at 1 and 10  $\mu$ M. At 1  $\mu$ M, **19** inhibited 23 proteins >70% whereas at 10  $\mu$ M, 76 proteins were inhibited >70%, Figure 5. Under both conditions, **19** more greatly inhibited ATR (inh = 96% and 106%, 1  $\mu$ M and 10  $\mu$ M, respectively) and breast tumor kinase (BRK, inh = 102%, 1  $\mu$ M and 10  $\mu$ M) than any others tested. Notable kinase hits >70% at 1  $\mu$ M include B-Raf (WT and V599E), DDR1, cKit (D816H and V560G) and FMS, Table 6. As the lead compound was derived from a BTK/PI3K\delta dual inhibitor library, we were pleased to observe that **19** only inhibited BTK to 25% and PI3K\delta to 42% at 1  $\mu$ M. Regarding kinases relevant to DNA damage repair, **19** appears selective for ATR over both ATM (inh = 28% at 1  $\mu$ M) and DNA-PK (inh = 59% at 1  $\mu$ M). Overall, **19** appears to be relatively selective with most activity related to the tyrosine kinase family.



Figure 5. Kinase map of 19 depicting hits >70% inhibition at 1  $\mu$ M of 394 kinases tested; atypical protein kinases such as ATR, ATM, mTOR and PRKDC are not listed. See Supplemental Information for full list of kinase activity.

Kinase	<b>Inh</b> (%)	Kinase	Inh (%)
ATR(h)	96	cKit(V560G)(h)	76
BRK(h)	102	FMS	76
B-Raf(V599E)(h)	93	TGFβR1	76
DDR1(h)	92	DNA-PK(h)	59
B-Raf(h)	89	PI3K\delta(h)	42
cKit(D816H)(h)	85	ATM(h)	28
ALK4(h)	80	BTK(h)	25

Table 6. Selected kinase panel results at 1 µM.

Lastly, we evaluated the *in vivo* properties of **19** by conducting pharmacokinetic (PK) studies in mice. Compound **19** was dosed as a solution at 2 mg/kg IV and 10 mg/kg PO. The results are summarized in Table 7. Compound **19** had good clearance in mice, but had poor oral bioavailability indicating improvements in adsorption might be beneficial for further development candidates.

Table 7. In vi	o mouse	pharmacokinetic	properties <sup>a</sup>	of <b>19</b> .
----------------	---------	-----------------	-------------------------	----------------

CL (L/h/kg)	<b>V</b> <sub>z</sub> (L/kg)	$\textbf{AUC}_{\textbf{PO}}\left(\mu M\boldsymbol{\cdot}h\right)$	$PO \; t_{1/2} \left( h \right)$	<b>F</b> (%)
1.33	2.15	0.212	2.28	2.83

<sup>a</sup>WinNonlin noncompartmental analysis.

Compound 1 was identified as a hit from an ATR biochemical screen of a BTK/PI3K $\delta$  dual inhibitor library. Systematic modifications of the scaffold helped to define the binding mode, particularly the importance of the 4-amino group and the 5-position nitrogen. Variations to the *N*-1 and *C*-3 substituents provided additional information, however more detailed studies are required to fully understand the binding pocket. Further modifications led to the discovery of **19**, a novel pyrazolopyrimidine-containing analogue that: (1) has an ATR IC<sub>50</sub> = 66 nM; (2) is selective for ATR over ATM and DNA-PK; (3) has acceptable mouse PK properties; and (4) represents a candidate for further cellular and *in vivo* profiling including proof-of-concept (PoC) studies.

#### Funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. It was funded by Medivation, now Pfizer Inc.

#### Acknowledgments

The authors would like to thank Amantullah Ansari and Kakoli Mukherjee for their scientific input and the Integral BioSciences analytical, bioanalytical and purification teams for their assistance. The kinase map was reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). This research was funded solely by Medivation, Inc.

#### **References and notes**

- 1. Jackson, S. P.; Bartek, J. Nature 2009, 461, 1071-1078.
- 2. Mazouzi, A.; Velimezi, G.; Loizou, J. I. Exp. Cell Res. 2014, 329, 85-93.
- 3. Kaelin, W. G. Nat Rev Cancer 2005, 5, 689-698.
- 4. Liang, Y.; Lin, S.-Y.; Brunicardi, F. C.; Goss, J.; Li, K. World J Surg 2008, 33, 661-666.
- 5. Fang, B. J. Med. Chem. 2014, 57, 7859–7873.
- 6. O'Connor, M. J. Mol. Cell 2015, 60, 547-560.
- Kim, G.; Ison, G.; McKee, A. E.; Zhang, H.; Tang, S.; Gwise, T.; Sridhara, R.; Lee, E.; Tzou, A.; Philip, R.; Chiu, H. J.; Ricks, T. K.; Palmby, T.; Russell, A. M.; Ladouceur, G.; Pfuma, E.; Li, H.; Zhao, L.; Liu, Q.; Venugopal, R.; Ibrahim, A.; Pazdur, R. *Clinical Cancer Research* 2015, 21, 4257–4261.
- 8. Plummer, R. Clin Oncol (R Coll Radiol) 2014, 26, 250–256.
- 9. Rabenau, K.; Hofstatter, E. Clinical Therapeutics 2016, 38, 1577–1588.
- 10. Wang, Y.-Q.; Wang, P.-Y.; Wang, Y.-T.; Yang, G.-F.; Zhang, A.; Miao, Z.-H. J. Med. Chem. 2016, 59, 9575-9598.
- 11. Wagner, J. M.; Kaufmann, S. H. Pharmaceuticals 2010, 3, 1311-1334.
- 12. Fokas, E.; Prevo, R.; Hammond, E. M.; Brunner, T. B.; McKenna, W. G.; Muschel, R. J. Cancer Treatment Reviews 2014, 40, 109-117.
- 13. Foote, K. M.; Lau, A.; M Nissink, J. W. Future Medicinal Chemistry 2015, 7, 873-891.
- 14. Hoekstra, M. F. Current Opinion in Genetics & Development 1997, 7, 170-175.
- 15. Kavanaugh, G.; Ye, F.; Mohni, K. N.; Luzwick, J. W.; Glick, G.; Cortez, D. DNA Repair 2015, 35, 55-62.
- 16. Prevo, R.; Fokas, E.; Reaper, P. M.; Charlton, P. A.; Pollard, J. R.; McKenna, W. G.; Muschel, R. J.; Brunner, T. B. *Cancer Biology & Therapy* **2014**, *13*, 1072–1081.
- 17. Mohni, K. N.; Thompson, P. S.; Luzwick, J. W.; Glick, G. G.; Pendleton, C. S.; Lehmann, B. D.; Pietenpol, J. A.; Cortez, D. PLoS ONE 2015, 10, e0125482.
- Pollard, J.; Reaper, P.; Peek, A.; Hughes, S.; Djeha, H.; Cummings, S.; Larbi, K.; Penney, M.; Sullivan, J.; Takemoto, D.; DeFranco, C. Cancer Research 2016, 76, 3711–3711.
- 19. Krajewska, M.; Fehrmann, R. S. N.; Schoonen, P. M.; Labib, S.; de Vries, E. G. E.; Franke, L.; van Vugt, M. A. T. M. Oncogene 2015, 34, 3474– 3481.
- Charrier, J.-D.; Durrant, S. J.; Golec, J. M. C.; Kay, D. P.; Knegtel, R. M. A.; MacCormick, S.; Mortimore, M.; O'Donnell, M. E.; Pinder, J. L.; Reaper, P. M.; Rutherford, A. P.; Wang, P. S. H.; Young, S. C.; Pollard, J. R. *J. Med. Chem.* 2011, 54, 2320–2330.
- 21. Foote, K. M.; Blades, K.; Cronin, A.; Fillery, S.; Guichard, S. S.; Hassall, L.; Hickson, I.; Jacq, X.; Jewsbury, P. J.; McGuire, T. M.; Nissink, J. W.
- M.; Odedra, R.; Page, K.; Perkins, P.; Suleman, A.; Tam, K.; Thommes, P.; Broadhurst, R.; Wood, C. J. Med. Chem. 2013, 56, 2125–2138.
  22. Barsanti, P. A.; Aversa, R. J.; Jin, X.; Pan, Y.; Lu, Y.; Elling, R.; Jain, R.; Knapp, M.; Lan, J.; Lin, X.; Rudewicz, P.; Sim, J.; Taricani, L.; Thomas, G.; Xiao, L.; Yue, Q. ACS Med. Chem. Lett. 2015, 6, 37–41.
- 23. Barsanti, P. A.; Pan, Y.; Lu, Y.; Jain, R.; Cox, M.; Aversa, R. J.; Dillon, M. P.; Elling, R.; Hu, C.; Jin, X.; Knapp, M.; Lan, J.; Ramurthy, S.; Rudewicz, P.; Setti, L.; Subramanian, S.; Mathur, M.; Taricani, L.; Thomas, G.; Xiao, L.; Yue, Q. ACS Med. Chem. Lett. 2015, 6, 42–46.
- 24. Pujala, B.; Agarwal, A. K.; Middya, S.; Banerjee, M.; Surya, A.; Nayak, A. K.; Gupta, A.; Khare, S.; Guguloth, R.; Randive, N. A.; Shinde, B. U.; Thakur, A.; Patel, D. I.; Raja, M.; Green, M. J.; Alfaro, J.; Avila, P.; Pérez de Arce, F.; Almirez, R. G.; Kanno, S.; Bernales, S.; Hung, D. T.; Chakravarty, S.; McCullagh, E.; Quinn, K. P.; Rai, R.; Pham, S. M. ACS Med. Chem. Lett. 2016, ASAP.
- Fokas, E.; Prevo, R.; Pollard, J. R.; Reaper, P. M.; Charlton, P. A.; Cornelissen, B.; Vallis, K. A.; Hammond, E. M.; Olcina, M. M.; Gillies McKenna, W.; Muschel, R. J.; Brunner, T. B. *Cell Death Dis* 2012, *3*, e441.
- Hall, A. B.; Newsome, D.; Wang, Y.; Boucher, D. M.; Eustace, B.; Gu, Y.; Hare, B.; Johnson, M. A.; Li, H.; Milton, S.; Murphy, C. E.; Takemoto, D.; Tolman, C.; Wood, M.; Charlton, P.; Charrier, J.-D.; Furey, B.; Golec, J.; Reaper, P. M.; Pollard, J. R. Oncotarget 2014, 5, 5674–5685.
- 27. Vendetti, F. P.; Lau, A.; Schamus, S.; Conrads, T. P.; O'Connor, M. J.; Bakkenist, C. J. Oncotarget 2015, 6, 44289-44305.

### Supplementary Material

Supplementary data associated with this article can be found online at doi:

### **Graphical Abstract**

To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered.

Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR)	Leave this area blank for abstract info.
Sreekanth A. Ramachandran, Pradeep S. Jadhavar, Manvendra F Kevin P. Quinn, Po-yin Wong, Andrew A. Protter, Roopa Rai, S	P. Singh, Ankesh Sharma, Gaurav N. Bagle, Son M. Pham and Jeffrey N. Lindquist

